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Background: This study investigated the influence of P-glycoprotein (P-gp) inhibitor tariquidar on the
pharmacokinetics of P-gp substrate radiotracer (R)-[11C]verapamil in plasma and brain of rats and humans by means
of positron emission tomography (PET).
Methods: Data obtained from a preclinical and clinical study, in which paired (R)-[11C]verapamil PET scans were
performed before, during, and after tariquidar administration, were analyzed using nonlinear mixed effects (NLME)
modeling. Administration of tariquidar was included as a covariate on the influx and efflux parameters (Qin and
Qout) in order to investigate if tariquidar increased influx or decreased outflux of radiotracer across the blood–brain
barrier (BBB). Additionally, the influence of pilocarpine-induced status epilepticus (SE) was tested on all model
parameters, and the brain-to-plasma partition coefficient (VT-NLME) was calculated.
Results: Our model indicated that tariquidar enhances brain uptake of (R)-[11C]verapamil by decreasing Qout. The
reduction in Qout in rats during and immediately after tariquidar administration (sevenfold) was more pronounced
than in the second PET scan acquired 2 h after tariquidar administration (fivefold). The effect of tariquidar on Qout in
humans was apparent during and immediately after tariquidar administration (twofold reduction in Qout) but was
negligible in the second PET scan. SE was found to influence the pharmacological volume of distribution of the
central brain compartment Vbr1. Tariquidar treatment lead to an increase in VT-NLME, and pilocarpine-induced SE lead
to increased (R)-[11C]verapamil distribution to the peripheral brain compartment.
Conclusions: Using NLME modeling, we were able to provide mechanistic insight into the effects of tariquidar and
SE on (R)-[11C]verapamil transport across the BBB in control and 48 h post SE rats as well as in humans.
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About one-third of patients with epilepsy are pharma-
coresistant and do not respond adequately to antiepilep-
tic drug therapy [1]. The blood–brain barrier (BBB) has
a major role in regulating the transport of antiepileptic
drugs to their target site of action. Drug penetration
across the BBB is influenced by several mechanisms,
such as passive diffusion, active influx, and active efflux.
Regional overactivity of efflux transporters at the BBB is
thought to contribute to drug resistance by impeding
therapeutically effective concentrations of antiepileptic
drugs at their sites of action [2]. P-glycoprotein (P-gp),
which is physiologically located at the luminal mem-
brane of brain capillary endothelial cells, is currently one
of the most widely studied efflux transporters at the
BBB. Positron emission tomography (PET) with carbon-
11-labeled P-gp substrates, such as (R)-[11C]verapamil or
[11C]-N-desmethyl-loperamide, has been evaluated as a
tool for in vivo imaging of P-gp function in different spe-
cies [3-6]. However, these radiotracers are high-affinity
P-gp substrates and consequently display very low brain
concentrations, limiting their suitability as PET tracers
[5,7,8]. This drawback can be overcome by modulation
of P-gp with the third-generation P-gp inhibitor tari-
quidar, which leads to increased brain uptake of
these radiotracers. After partial inhibition of P-gp with
3 mg/kg tariquidar, regional differences in P-gp expres-
sion and functionality between naïve and status epilepti-
cus (SE) rats become evident [9,10]. Additionally, P-gp
at the BBB has been found to be upregulated after acute
seizure activity like SE or in chronic epilepsy [11-15].
Further, species-dependent differences in P-gp expres-
sion and functionality at the BBB have been described
and discussed in literature [16-18], including the P-gp
mediated interaction between (R)-[11C]verapamil and
tariquidar at the human and rat BBB studied by Bauer
et al. [18]. Despite several published studies, there is still
an ongoing debate, whether P-gp inhibition with tariqui-
dar or other inhibitors is enhancing the brain uptake of
substrate radiotracers by increasing the influx or de-
creasing outflux across the BBB of the radiotracer [9].
In PET research, pharmacokinetic (PK) modeling
(compartment modeling) is used for detailed quantitative
analysis of PET data. Each individual is analyzed separ-
ately, and group averages and variability are subse-
quently based on the individual estimates. An alternative
way to analyze PK-pharmacodynamic (PD) data is non-
linear mixed effects (NLME) modeling, often referred to
as population modeling. This modeling approach is rou-
tinely used in pharmaceutical research and has also
found to be suitable for PET research [19-29]. A popula-
tion approach analyzes data from all subjects simultan-
eously and gives a description of the PK in the typical
subject as well as the variation in the study population.Syvänen et al. [26] analyzed data from a (R)-[11C]verap-
amil PET study in naïve and post SE rats (seven days
after kainate treatment) with both a PET PK-modeling
approach and a NLME-modeling approach and con-
cluded that both approaches produced similar PK par-
ameter estimates, but that NLME modeling provided
more precise parameter estimates.
In the present study, we analyzed data obtained from
a preclinical PET study in naïve rats and rats at 48 h
after pilocarpine-induced SE [9] and a clinical study in
healthy volunteers [30]. In both studies, subjects under-
went paired (R)-[11C]verapamil PET scans before, dur-
ing, and after administration of tariquidar (rats, 3 and
15 mg/kg; humans, 2 mg/kg) (see Figure 1). Tariquidar
was administered during the first PET scan and PET
data acquisition continued during and after tariquidar
administration. Both in rats and in humans a pro-
nounced and immediate increase in (R)-[11C]verapamil
brain uptake during treatment with tariquidar was
observed. In the original analysis of the rat data [9],
(R)-[11C]verapamil brain curves obtained during and
after tariquidar treatment in the first PET scan (60 to
140 min) were not included in PET PK modeling as
standard PET approaches do not handle this type of
data. In the original analysis of the human data [30],
however, efforts were made to analyze the time course
of the effect of tariquidar administration on activity in
brain during the first PET scan using an indirect re-
sponse PK-PD model proposed by Syvänen et al. [31]
(see supplemental data of Wagner et al. [30]). These
results suggested that the (R)-[11C]verapamil brain
curves obtained during and immediately following tari-
quidar treatment may contain important information
that may contribute to the model structure and param-
eter outcome. Therefore, we hypothesized that the use
of NLME modeling may provide mechanistic informa-
tion of the PK of (R)-[11C]verapamil in plasma and
brain including quantification of the influence of
tariquidar-induced P-gp inhibition and pilocarpine-
induced SE on (R)-[11C]verapamil brain and plasma
PK. The specific aims of this study were to investigate
whether the observed increase in (R)-[11C]verapamil
brain uptake during and immediately after tariquidar
treatment influences PK model parameter estimates
and if regional differences in certain brain regions as
recently discussed by Bankstahl et al. [9] become more
pronounced when these data are included in the ana-
lysis. Additionally, it was studied whether the enhance-
ment of brain uptake of (R)-[11C]verapamil after
tariquidar administration was caused by increased in-
flux or decreased outflux of the radiotracer. Finally, the
developed model based on the rat dataset was applied
to the human data set to identify potential species dif-
ferences in P-gp function.
Figure 1 Scheme of the setups for the preclinical study (A) and the clinical study (B).
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Preclinical data set
The preclinical dataset was recently published by
Bankstahl et al. [9], and the study setup is illustrated in
Figure 1A. The study was approved by the Institutional
Animal Care and Use Committee, and all study proce-
dures were performed in accordance with the European
Communities Council Directive of November 24, 1986
(86/609/EEC). All efforts were made to minimize
both the suffering and the number of animals used in
this study.
Naïve control (n = 11) and 48-h post SE (n = 10) fe-
male Sprague–Dawley rats (Harlan Nederland, Horst,
Netherlands) weighing 260±28 g underwent paired (R)-
[11C]verapamil PET scans. The number of animals, ani-
mal weights, injected doses, and injection times of all
treatment groups are summarized in Table 1. All rats
underwent a 140-min dynamic baseline PET scanTable 1 Number of animals (n), weight at time of PET, injecte











Body weight (g) 260 ± 5 307 ± 1
Baseline (R)-[11C]verapamil (MBq) 97 ± 27 88 ± 1
I.V. injection time (sec) 18 ± 7 39 ± 1
Post-inhibition (R)-[11C]verapamil (MBq) 93 ± 27 101 ± 2
I.V. injection time (sec) 18 ± 6 36 ± 5starting simultaneously with (R)-[11C]verapamil adminis-
tration given as an intravenous bolus (I.V.) on a micro-
PET Focus 220 scanner (Medical Solutions, Siemens
Knoxville, TN, USA). Tariquidar (3 or 15 mg/kg) was
administered at 60 min after the start of the baseline
scan as an I.V. bolus over 60 sec. A second 60-min
dynamic (R)-[11C]verapamil PET scan, referred to as
post-inhibition scan, was started 2 h after tariquidar ad-
ministration. In parallel to the measurement of (R)-[11C]
verapamil brain concentrations with PET, (R)-[11C]ver-
apamil concentration in blood and plasma (mean
plasma-to-blood ratio of (R)-[11C]verapamil = 1.29±0.10
[32]) was obtained with continuous arterial blood sam-
pling. In addition, (R)-[11C]verapamil concentration in
plasma was corrected for radiolabelled metabolites.
More information on the PET scan procedure, the study
setup, the arterial blood sampling, and the metabolite
correction can be found in the previously publishedd doses (average ± standard deviation) of (R)-[11C]














8 234 ± 14 247 ± 16 260 ± 28
7 84 ± 20 94 ± 25 91 ± 22
0 19 ± 2 25 ± 11 24 ± 11
8 91 ± 9 92 ± 16 94 ± 21
16 ± 2 32 ± 18 24 ± 13
Table 2 Number of human volunteers (n), weight at time
of PET, injected doses (average ± standard deviation) of
(R)-[11C]verapamil for baseline, and post-inhibition scans





Body weight (kg) 74±5
Baseline (R)-[11C]verapamil (MBq) 379±11
I.V. injection time (sec) 51±10
Post-inhibition (R)-[11C]verapamil (MBq) 389±15
I.V. injection time (sec) 43±11
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For modeling, (R)-[11C]verapamil concentration-time
curves before and after tariquidar administration,
expressed in units of kilobecquerels per milliliters (kBq/
ml), were extracted from eight brain regions of interest
(whole brain (WB), corpus striatum (CS), entorhinal cor-
tex (EC), septal hippocampus (Shipp), temporal hippo-
campus (THipp), thalamus (Th), cerebellum (Cer), and
frontal motor cortex (FMC)) as described previously
[10]. For comparison with human data, activity concen-
trations were normalized to injected activity per body
weight and expressed as standardized uptake value
(SUV).
Clinical data set
The clinical dataset has been described in detail by
Wagner et al. [30]. The study setup is illustrated in
Figure 1B. The study protocol was approved by the local
Ethics Committee and was performed in accordance
with the Declaration of Helsinki (1964) in the revised
version of 2000 (Edinburgh), the Guidelines of the Inter-
national Conference of Harmonization, the Good Clin-
ical Practice Guidelines, and the Austrian Drug Law
(Arzneimittelgesetz). All subjects were given a detailed
description of the study, and their written consent was
obtained before they enrolled in the study.
Five healthy male volunteers with an average age of
32±8 years and an average body weight of 74±5 kg
underwent paired (R)-[11C]verapamil PET scans of 120-
and 40-min duration, respectively, with an interval of
2 h between the two scans on an Advance PET scanner
(GE Medical Systems, Waukesha, WI, USA). Dynamic
PET and arterial blood sampling were started at the time
of radiotracer injection. Forty minutes after the start of
the baseline scan, tariquidar was administered at a dose
of 2 mg/kg of body weight I.V. over 30 min. Post-
inhibition scan was performed at 2 h and 50 min after
the end of tariquidar infusion. Number of participants,
body weight, injected doses, and radiotracer injection
times are summarized in Table 2.
For modeling, (R)-[11C]verapamil concentration-time
curves before and after tariquidar administration,
expressed in kBq/ml, were extracted from a WB gray
matter region as described previously [30].
PK modeling: PET approach
PET PK modeling parameters for rats and human were
taken from Bankstahl et al. [9] and Wagner et al. [30],
respectively. Individual profiles from each animal or
human were analyzed using the common data analysis
approaches for PET (PK modeling of individual profiles)
[33,34]. In both studies, a two-tissue-4-rate constant
(2T4K) compartment model was applied to estimate the
brain-to-plasma partition coefficient, referred to as thevolume of distribution in PET literature (VT-2T4K), and
the rate constants describing exchange of radioactivity
between the plasma and the two brain tissue compart-
ments. To further obtain a model-independent estimate
of the brain-to-plasma partition coefficient, Logan
graphical analysis [34] was used (VT-Logan). Data
obtained during and immediately after tariquidar treat-
ment, i.e., the last part of the baseline scans, were not
included when estimating VT-2T4K and VT-Logan.
NLME modeling
For modeling of the metabolite-corrected plasma and
brain concentration-time curves during the entire scan
period, NLME modeling in NONMEM VI (GloboMax
LLC, Hanover, MD, USA) was applied in order to pre-
dict the rate constants describing the PK of (R)-[11C]ver-
apamil and the effects of tariquidar on (R)-[11C]
verapamil PK. Data from all subjects and all scans were
analyzed simultaneously to yield population estimates of
PK parameters as well as estimates of inter-animal vari-
ability. Covariate analysis allowed for the identification
of the specific sources of variability. The subroutine
ADVAN 9 and first-order conditional estimation with
interaction were used throughout the modeling proced-
ure. Model selection was based on the objective function
value (OFV, the lowest value corresponds to the best
model), model parameter uncertainty, and graphic ana-
lysis using Xpose 4 [35] implemented in software R
2.7.1. (The R Foundation for Statistical Computing).
Outcome parameters were viewed and compared in
Census [36]. For nested models, OFV reductions of 3.83,
6.63, and 10.83 units correspond to improved fits at p <
0.05, p < 0.01, and p < 0.001 levels. The inter-individual
variation of the parameters was described by the expo-
nential variance model:
θi ¼ θpop  exp ηi
 
; ð1Þ
where θi is the parameter in the ith animal, θpop is the
parameter in a typical animal, and ηi is the inter-animal
Figure 2 The final population model. Vc, Vp1 and Vp2 are the
pharmacological volumes of distribution in central and two
peripheral plasma compartments, while Vbr1 and Vbr2 are the
volumes of distribution in central and peripheral brain
compartments, respectively. CL, Q1, Q2, Qin, Qout, and Qbr are total
body clearance, bidirectional clearance between plasma and
peripheral compartment 1, bidirectional clearance between plasma
and peripheral compartment 2, clearance into the brain, clearance
out of the brain, and bidirectional clearance between central and
peripheral brain compartments, respectively. Plus sign (+) indicates
an increase in Vbr1 due to rat group (EffSE) and the effect of
tariquidar (Efftariquidar), resulting in a decrease in Qout. Asterisk (*)
indicates the parameter estimates, which were fixed during
modeling procedure, though Vbr2 was only fixed in rats.
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around zero with a standard deviation ω, to distinguish
the ith animal from the typical value as predicted from
the regression model. Inter-animal variation was studied
on all parameters and was included if the model was
improved significantly (OFV > 3.83). To test the signifi-
cance of the covariate inclusion, e.g., effect of tariquidar
and SE, a stepwise forward addition and backward dele-
tion approach was applied, and covariates were only kept
in the model if they significantly improved the model.
Finally, proportional error models were included for the
residual variability, i.e., variability that remained unex-
plained after inclusion of inter-animal variability and
covariates. More comprehensive description of NLME
modeling can be found elsewhere, for example in the
paper by Pillai et al. [37].
The model development was carried out using the
rat dataset (WB region) and the model was built in se-
quential steps. The first step was to develop a PK
model for (R)-[11C]verapamil plasma concentration-
time profiles. Two and three compartment models were
evaluated. Treatment (tariquidar-treated or tariquidar-
untreated) and rat group (control or 48-h post SE)
were defined as covariates (Efftariquidar and EffSE) and
their effects on the parameter estimates were studied.
Next, a PK model of (R)-[11C]verapamil concentration-
time profiles in brain was developed. Two and three
compartment models were evaluated, and again treat-
ment and rat group were defined as covariates. Finally,
in the last step of the model development, the PK
models for (R)-[11C]verapamil kinetics in plasma and
brain were merged.
The increased uptake of (R)-[11C]verapamil into the
brain after administration of tariquidar was assumed to
be either due to increased transport of (R)-[11C]verap-
amil into the brain (i.e., increased Qin, Equation 2) or
decreased transport of (R)-[11C]verapamil out of the
brain (i.e., decreased Qout, Equation 3) [25].
dVERbr1
dt
¼ D⋅Qin⋅VERc  Qout⋅VERbr1 ð2Þ
dVERbr1
dt
¼ Qin⋅VERc  D⋅Qout⋅VERbr1 ð3Þ
dVERbr2
dt
¼ Qbr⋅VERbr1  Qbr⋅VERbr2; ð4Þ
where VERbr1 and VERc are the (R)-[
11C]verapamil con-
centrations in the central brain compartment and in
plasma, respectively, and D (Equations 2 and 3)
describes the effect of tariquidar on the transport of (R)-
[11C]verapamil between plasma and brain. D was consid-
ered to affect the clearance out of the brain (Qout) or the
clearance into the brain (Qin). Qbr is the bidirectional
clearance between the central and the peripheral braincompartments (see also Figure 2). Different models for
describing D were tested, including indirect effect mod-
els based on tariquidar plasma concentration or admi-
nistered dose or as a combination of categorical
covariates for tariquidar treatment and scan (see
‘Results’ section). A second (peripheral) brain compart-
ment was evaluated for (R)-[11C]verapamil, where
VERbr2 is the (R)-[
11C]verapamil concentration in the
peripheral slow equilibrating brain compartment (Equa-
tion 4). The final PK model developed for the WB region
of the rat was then applied to the selected brain regions
of interest (CS, EC, Shipp, THipp, Th, Cer, and FMC),
respectively. To investigate whether the increase of (R)-
[11C]verapamil brain uptake during and after treatment
with tariquidar (60 to 140 min of baseline scan) influ-
enced the model outcome parameters, the final model
was applied to the first 60 min of the baseline (i.e., ex-
cluding the data acquired during and immediately after
tariquidar administration) and the post-inhibition scan
only. The effect of tariquidar (D) was studied on the Qin
and the Qout of (R)-[
11C]verapamil brain uptake. Add-
itionally, the model was applied to the human data set,
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apamil brain concentrations during and after the tariqui-
dar administration (40 to 120 min of baseline scan) on
the model outcome parameters was evaluated. Volume
of distribution (VT-NLME) was calculated as the ratio Qin/
Qout and compared with VT-2T4K values obtained with
standard PET PK modeling.
Statistics
Differences between groups were analyzed by 2-way
ANOVA including Bonferroni correction using PRISM 5
software (GraphPad Software, La Jolla, CA). The level of
statistical significance was set to p < 0.05.
Results
WB (R)-[11C]verapamil time-activity curves expressed as
SUV at baseline and in the post-inhibition scan are
shown for naïve and 48-h post SE rats in Figure 3 and
for humans in Figure 4. Both in rats and humans, tari-
quidar administration during the baseline scan resulted
in an immediate rise in brain activity concentrations.
NLME modeling of plasma and brain PK with and without
tariquidar administration
NLME modeling was used to study the kinetics of (R)-
[11C]verapamil in plasma and brain. Metabolite cor-
rected plasma curves were best described with a three
compartment model. Inclusion of covariates for de-
scribing the effect tariquidar treatment (Efftariquidar) and
rat group (EffSE) did not result in a significant model
improvement, when applied to any of the PK para-
meters of the plasma model and were, therefore, notFigure 3 WB (R)-[11C]verapamil time-activity curves in rats. Average ±
WB expressed as SUV for naïve (squares) and 48-h post SE (circles) animals
Tariquidar (3 mg/kg) was administered 60 min after the start of the baselinincluded. Parameter estimates, the relative standard
error (%), and the inter-animal variability for the
plasma model are given in Table 3. Brain PK in both
rats and humans was best described with a two-
compartment model. The brain model was combined
with the plasma PK model. For rats, plasma parameter
estimates were fixed according to the best plasma
model (see Table 3). In addition, the pharmacological
volume of distribution of the peripheral brain compart-
ment, Vbr2, was fixed to a value of 2 ml, i.e. the total
volume of a rat brain [38]. All other brain parameter
estimates were allowed to freely change. For the human
data, plasma parameters were also fixed, whereas the
brain parameter estimates were allowed to freely
change. The final model is shown in Figure 2, and the
model diagnostics plots for the rat model are shown in
Figure 5. Population parameter estimates of the (R)-
[11C]verapamil brain model for all studied brain regions
of interest are shown in Table 4 for rats and humans.
(R)-[11C]verapamil concentration-time profiles in rats
and model predictions of WB (data from 0 to 140 min
and 180 to 240 min) and WB* (data from 0 to 60 min
and 180 to 240 min) are shown in Figure 6. For the
human data modeling, results of (R)-[11C]verapamil
concentration-time curves of the WB gray matter (data
from 0 to 120 min and 240 to 280 min) and WB* gray
matter (data from 0 to 40 min and 240 to 280 min)
are shown in Figure 7. Structural model parameters
were obtained for the clinical data (Table 3), but due
to the relatively small sample size (n = 5), reliable esti-
mates of inter-individual variation and standard devia-
tions could not be obtained.standard deviation (R)-[11C]verapamil concentration-time curves in rat
at baseline (open symbols) and at post-inhibition (full symbols).
e scan as an I.V. bolus over 60 sec (arrow).
Figure 4 WB (R)-[11C]verapamil time-activity curves in humans. Average ± standard deviation (R)-[11C]verapamil concentration-time curves in
human WB gray matter expressed as SUV at baseline (open symbols) and at post-inhibition (full symbols). Tariquidar (2 mg/kg) was administered
40 min after the start of the baseline scan as an infusion over 30 min (arrow).
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across the BBB
To investigate the mechanism of P-gp inhibition, tari-
quidar treatment was included as a covariate for the
influx clearance from the plasma compartment into
the first brain compartment (Qin) or for the effluxTable 3 Population parameter estimates and relative
standard errors (%) of the (R)-[11C]verapamil plasma
model using mixed effects modeling of the WB region of






Vc (ml) 38.8 0.162 2580
(7.27) (52.3) (−)
Vp1 (ml) 141 0.169 57900
(17.6) (23.3) (−)
Vp2 (ml) 1580 - 41100
(17.6) (−)
CL (ml·min−1) 16.4 0.162 538
(10.3) (52.3) (−)
Q1 (ml·min
−1) 29.1 0.169 6550
(7.77) (23.3) (−)
Q2 (ml·min
−1) 22.3 0.162 5880
(10.0) (52.3) (−)
Residual error plasma 0.482 - 0.654
(6.93) (−)
For definition of parameters, please refer to the legend of Figure 2. The RSA
are given in parentheses after the estimates.clearance from the first brain compartment into the
plasma compartment (Qout). The effect (D) of tari-
quidar treatment was best described as a combination
of two categorical covariates and was defined as:
D ¼ Efftariquidar3 covð Þ  Effscan covð Þ
cov ¼ 0 or 1 ð5aÞ
D ¼ Efftariquidar15 covð Þ  Effscan covð Þ
cov ¼ 0 or 1 ð5bÞ
Efftariquidar3 and Efftariquidar15 are the estimated effects
of tariquidar for the 3 and 15 mg/kg doses, respectively.
The exponent, cov, was assigned to a value of 0 when
no tariquidar was administered or 1 when tariquidar
was administered. Effscan describes the difference in tar-
iquidar effect between baseline and post-inhibition
scans. The exponent, cov, of Effscan was assigned to a
value of 0 and 1 for the baseline and post inhibition
scan, respectively. The total effect of tariquidar inhib-
ition, D, was therefore the fractional change in trans-
port caused by tariquidar while also taking into
account changes of tariquidar-induced P-gp inhibition
occurring between the two scans (baseline or post-in-
hibition) as it is likely that the inhibition is changing
due to the elimination of tariquidar from the plasma
and brain.
OFV was found to be lower when tariquidar treatment
affected Qout (Equation 3) compared when tariquidar
treatment affected Qin (Equation 2) in all studied brain
regions. For example, in WB, the effect of tariquidar on
Qout yielded an OFV (the lowest value corresponds to
the best model) of −1,676, while the effect of tariquidar
Figure 5 Diagnostic plots for the final population model including both brain and plasma (R)-[11C]verapamil concentrations. Each
individual data point is represented by one dot. The red line represents the average observation. Observations are plotted against population
predictions (upper left panel) and individual predictions (upper right panel). Data points are randomly distributed along the line of identity,
indicating that the concentrations are adequately described by the model. Absolute individual weighted residuals versus individual predictions
(lower left panel) and weighted residuals versus time (lower right panel) are plotted. Most residuals are clustered around zero, while there are
outliers at early time points.
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model was applied to the dataset, excluding data
acquired during and after tariquidar administration.
Again, the OFV was lower in all regions when the tari-
quidar effect was applied on Qout compared to Qin.
Parameter estimates, when including or excluding the
data acquired during and immediately after tariquidar
administration, were in general comparable. The par-
ameter estimates for the whole brain regions when in-
cluding (WB) and excluding (WB*) this data are given
in Table 4. In Figure 8E, Qin and Qout values for base-
line scans in rats are shown. At baseline, statistically
significant differences between Qin and Qout were
observed for all brain regions in rats, except for FMC.
In all outlined brain regions Qout was higher than Qin,
while in WB, Qin was higher than Qout. Additionally, in
all brain regions, Qout was decreased during and after
tariquidar administration as compared with baseline
scans (Figure 8F). Mean decrease in Qout relative to
baseline scan was −84±5% for 3 mg/kg and −86±4%
for 15 mg/kg tariquidar. For the 3 mg/kg tariquidar
group, largest decreases of Qout relative to baseline scanwere found for CS (−89%, Efftariquidar = 0.11) followed
by SHipp (−88%, Efftariquidar = 0.12) and Th (−88%,
Efftariquidar = 0.12), and smallest decreases were found
for Cer and EC (both −77%, Efftariquidar = 0.23)
(Table 4). For the 15 mg/kg tariquidar group, largest
decreases in Qout were found in CS, SHipp, and Th
(all −90%, Efftariquidar = 0.10), and smallest decreases
were found in EC (−79%, Efftariquidar = 0.215)
(Table 4). In summary, there was a trend that Qout
was further reduced in 15 mg/kg as compared with
3 mg/kg tariquidar treated animals in all regions
(Figure 8F). However, the difference in Qout between
3 and the 15 mg/kg treated animals was statistically
significant only in Cer. Also when comparing Qout
estimated when data during and immediately after
tariquidar administration was excluded, Cer was the
only region in which Qout differed between 3 and the
15 mg/kg treated animals (Figure 8G). When exclud-
ing the data during and immediately after tariquidar
administration, mean decrease of Qout relative to
baseline scans was −78±7% for 3 mg/kg and −82±6%
for 15 mg/kg tariquidar (Figure 8G). Thus, Qout was
Table 4 Population parameter estimates and relative standard errors (%) of (R)-[11C]verapamil brain model are shown
for all investigated brain regions
Species
Rat Human
Brain region WB*,a WBb CS EC SHipp THipp Th Cer FMC WB*,a WBb
OFV −604 −1676 −1420 −1652 −1500 −954 −1559 −1562 −1365 7799 −357
Model parameters
Vbr1 (ml) 0.132 0.132 0.119 0.155 0.151 0.129 0.156 0.192 0.088 2.29 3.17
(10.5) (11.3) (10) (11.4) (9.74) (27.2) (12.2) (19.2) (15.8) (−) (−)
Vbr2 (ml) 2 2 2 2 2 2 2 2 2 13.0 18.4
(−) (−) (−) (−) (−) (−) (−) (−) (−) (−) (−)
Qin (ml·min
−1) 5.48 5.62 2.05 3.32 2.49 1.98 2.43 2.44 1.79 713 588
(13.0) (12.5) (12.8) (16.8) (12.7) (24.5) (11.3) (14.2) (19.2) (−) (−)
Qout (ml·min
−1) 3.56 3.60 3.45 3.91 4.56 2.99 4.39 3.01 1.97 1410 1080
(12.6) (12.5) (12.5) (16.3) (12.5) (21.8) (11.3) (13.9) (19.1) (−) (−)
Qbr (ml·min
−1) 0.115 0.115 0.114 0.111 0.113 0.108 0.129 0.118 0.12 1.26 1.71
(3.2) (3.05) (3.43) (3.71) (3.87) (4.63) (3.45) (3.24) (3.58) (−) (−)
Residual error brain 0.404 0.382 0.44 0.387 0.421 0.571 0.016 0.407 0.454 0.295 0.27
(5.1) (4.61) (5.3) (6.25) (4.18) (14.4) (3.93) (5.72) (6.32) (−) (−)
Covariates
Effect of pilocarpine induced SE
EffSE
c 1.84 1.84 1.88 1.73 1.86 2.21 1.77 0.924 2.3 (−) (−)
(10.4) (11.7) (13.8) (13.5) (13.2) (24.7) (12.9) (20.5) (15.8)
Effect of tariquidar
Efftariquidar (3 mg/kg or 2 mg/kg)
d 0.219 0.161 0.114 0.233 0.119 0.15 0.12 0.226 0.194 0.993 0.483
(5.84) (4.16) (3.89) (5.54) (5.49) (5.51) (5.33) (5.31) (4.42) (−) (−)
Efftariquidar (15 mg/kg)
d 0.168 0.135 0.101 0.215 0.101 0.134 0.103 0.148 0.155 (−) (−)
(5.22) (6.94) (7.71) (6.56) (9.3) (7.61) (9.01) (8.65) (7.74) - -
Effect of scan on tariquidar
induced P-gp inhibition
Effscan
d (−) 1.33 1.29 1.37 1.29 1.25 1.21 1.52 1.4 (−) 2.28
- (5.67) (6.78) (5.47) (7.1) (6.21) (6.08) (6.97) (6.06) - (−)
All (R)-[11C]verapamil plasma model parameter estimates outlined in Figure 2, obtained from final plasma model were fixed and the parameter estimate for the
second brain compartment Vbr2 was fixed in rats to 2 ml. Parameters are given for the whole brain excluding (WB
*) and including (WB) the increase of (R)-[11C]
verapamil brain uptake during and after treatment with tariquidar, corpus striatum (CS), entorhinal cortex (EC), septal hippocampus (SHipp), temporal
hippocampus (THipp), thalamus (TH), cerebellum (Cer), and frontal motor cortex (FMC) for rat; WB* and WB for human. aWB* is the whole brain region excluding
data from 60 to 140 min rat or 40 to 120 min human (baseline and post-inhibition scan are considered, as used for kinetic modeling). bWB is the whole brain
region including data from 60 to 140 min rat or 40 to 120 min human (baseline, during, and after tariquidar, and post-inhibition scan are considered). cEffSE was a
significant covariate on Vbr1.
dThe effect of tariquidar, Efftariquidar, is on Qout the efflux clearance from the central brain compartment to the plasma compartment,
while Effscan also takes into account changes occurring between scans (baseline or post-inhibition).
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inhibition scan as compared to the last part of the first
scan when tariquidar had been administered (comparison
between Figure 8F and Figure 8G). In humans, Qout was
1.8-fold higher than Qin in the baseline scan (Figure 8D).
Qout during and after tariquidar administration was
decreased by −52% compared with Qout at baseline
(Efftariquidar = 0.48) (Figure 8H, Table 4). During the
post-inhibition scan, Qout was completely restored to
its baseline value (Efftariquidar = 0.99).Volume of distribution (VT-NLME)
VT-NLME (Qin/Qout) values at baseline and after tariqui-
dar administration are shown in Figure 8A,B,C,D for rats
and humans. Tariquidar increased VT-NLME by approxi-
mately 6.2-fold after 3 mg/kg dose and 7.4-fold after 15
mg/kg dose in the whole brain region when all data were
analyzed (Figure 8C). VT-NLME increase was lowest in EC
(fourfold) and highest in CS (ninefold) for the 3 mg/kg
tariquidar treated group. Also, for the 15 mg/kg tariqui-
dar group, VT-NLME increase was lowest in EC (fivefold)
Figure 6 Modeling results of (R)-[11C]verapamil concentration-time curves in WB of rats in ln(Bq/ml) over time (min). (A) WB was
compared with (B) WB* excluding the increase of (R)-[11C]verapamil brain uptake after treatment with tariquidar from 60 to 140 min. Tariquidar (3
or 15 mg/kg) was administered at 60 min after start of tracer injection as an I.V. bolus over 60 sec and the post-inhibition scan was started 2 h after
tariquidar administration. Each panel represents one animal (not all 21 are shown), open gray circles represent measurements (DV), solid red lines
represent the model predictions for individual rats (IPRE), and broken blue lines represent the population model predictions (PRED).
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http://www.ejnmmires.com/content/2/1/58and highest in CS (tenfold). VT-NLME was slightly
decreased when the data acquired during and immedi-
ately after tariquidar administration (scan 1, 60 to 140
min) was excluded. This was the result of a slightly
decreased Efftariquidar in the second scan compared to
the first scan. In humans, a twofold increase in VT-NLME
relative to baseline was observed during and after tari-
quidar administration (Figure 8D). In contrast, VT-NLME
was unchanged in the post-inhibition scan as compared
with baseline (Figure 8D).Figure 7 Modeling results of (R)-[11C]verapamil concentration-time cu
matter was compared with (B) WB* gray matter excluding the increase of (R
(2 mg/kg) was administered at 40 min after start of tracer injection as an int
50 min after end of tariquidar infusion. Each panel represents one volunteer
represent the model predictions for each individual subject (IPRE), and brokThe influence of rat group (status epilepticus)
The model was improved when EffSE was included as a
covariate for the volume of distribution of the central
brain compartment Vbr1:
Vbr1;ind ¼ Vbr1;pop  EffSE covð Þ cov ¼ 0 or 1; ð6Þ
where EffSE is the estimated influence of pilocarpine-
induced SE on Vbr1 (Equation 6) and implies a fractional
difference between control and 48-h post SE rats. Hence,rves in WB gray matter in ln(Bq/ml) over time (min). (A) WB gray
)-[11C]verapamil brain uptake after treatment with tariquidar. Tariquidar
ravenous infusion over 30 min and post-inhibition scan was started 2 h
, open gray circles represent measurements (DV), solid red lines
en blue lines represent the population model predictions (PRED).
Figure 8 Brain-to-plasma partition coefficients (A-D) and transport clearances across the BBB (E-H). (A) VT-NLME in rats at baseline, (B) VT-
NLME in rats during and after tariquidar administration, (C) VT-NLME in rats in post-inhibition scan, and (D) VT-NLME in WB in humans at baseline (VT),
during and after tariquidar administration (VT (2 mg/kg)) and in post-inhibition scan (V
*
T(2 mg/kg)). (E) Qin and Qout in rats at baseline, (F) Qout in
rats during and after tariquidar administration (3 or 15 mg/kg), (G) Qout in rats in post-inhibition scan, and (H) Qin, Qout at baseline, Qout during
and after tariquidar administration (2 mg/kg), and Q*out in post-inhibition scan (2 mg/kg) in humans. *p < 0.05, **p < 0.01, ***p < 0.001; not
significant p > 0.05.
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of 0 for the control rat group, while it was assigned to a
value of 1 for the 48-h post SE group.
EffSE was found to be a significant covariate that
increased Vbr1 in 48-h post SE rats as compared with
control rats (see Figure 2, Table 4) in all brain regions
except Cer. The largest increase in Vbr1 in the 48-h postSE group was observed for FMC (+130%, EffSE = 2.3)
and in THipp (+121%, EffSE= 2.21) (Table 4). In Cer, a
small decrease in Vbr1 for 48-h post SE rats as compared
with naïve rats was found (−8%, EffSE = 0.92). EffSE was
not considered for the analysis of the human data set
due to the fact that only healthy subjects participated in
the clinical study.
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In the present study, we used NLME modeling to study
the PK of (R)-[11C]verapamil in plasma and brain, and
the influence of tariquidar on (R)-[11C]verapamil brain
PK to gain better insight into the mechanism of P-gp
modulation by tariquidar. Moreover, our goal was to
evaluate if the increase in brain activity induced by tari-
quidar during the first PET scan is better suited to de-
scribe regional and species differences and differences
between control and post SE rats in cerebral P-gp func-
tion/expression as compared with using data from the
post-inhibition scan alone. The developed model
described the rat data well (Figure 6) and was then used
to model the clinical data set. The small number of
human subjects made it difficult to obtain estimates of
the inter-individual variation in the human data set, but
the model converged and, although the fit was not per-
fect, provided estimates of all structural model para-
meters. However, the variation in the human PK data set
between the five subjects was rather large, and in com-
bination with the few subjects, the results should be
interpreted with some caution.
During model development we tested certain indirect
response models [39] as used by Syvänen et al. [25],
which either incorporate tariquidar plasma concentra-
tion or administered dose to describe the effect of tari-
quidar on (R)–[11C]verapamil exchange between plasma
and brain. These models described (R)–[11C]verapamil
kinetics well, but were not able to estimate the half max-
imum effect dose (ED50) of tariquidar for P-gp inhibition
properly as our study only contained two dose groups (3
and 15 mg/kg tariquidar). Thus, a simplified modelTable 5 Comparison of volumes of distribution (VT) values of
analysis, PK modeling, and nonlinear mixed effects modeling
Sample Logan analysisa PK mod
WB* Cer WB*
Control rats
Baseline 1.6 (16) 2.0 (19) 1.8 (16)
Post-inhibition 7.6 (13) 6.1 (9) 7.8 (14)
Increase after 3 mg/kg tariquidarb 4.8-fold 3.1-fold 4.4-fold
48-h post SE rats
Baseline 1.4 (8) 1.3 (7) 1.5 (12)
Post-inhibition 7.4 (11) 3.5 (13) 7.6 (12)
Increase after 3 mg/kg tariquidarb 5.5-fold 2.6-fold 5.1-fold
Human
Baseline scan 0.64 (1) 0.65 (6)
Post-inhibition 0.79 (1) 0.80 (2)
Increase after 2 mg/kg tariquidarb 1.2-fold 1.2-fold
VT values were expressed as average and relative standard errors (%) for the WB reg
were obtained from Bankstahl et al. [9] for rats and from Wagner et al. [30] for hum
the estimated covariate effect Efftariquidar(1/Efftariquidar).describing the effect of tariquidar as a categorical covari-
ate was used. The decline in effect of tariquidar between
the two scans, due to tariquidar elimination, was
accounted for by a second categorical covariate (Effscan).
The appropriateness of the model was confirmed as
Efftariquidar*Effscan when including all data equaled
Efftariquidar when omitting data during and immedi-
ately after tariquidar administration. We defined the
NLME model in terms of clearances (ml/min) be-
tween model compartments and volumes of distribu-
tion (ml) as this is standard in conventional PK
analysis. To compare different modeling approaches,
we calculated VT values from the outcome para-
meters obtained with NLME modeling (VT-NLME as
the ratio Qin/Qout) and compared them with the respect-
ive VT-2T4K values obtained with standard PK modeling
[9,30]. Overall, VT-2T4K obtained with PET PK modeling
and VT-NLME obtained with NLME modeling were com-
parable. Tariquidar decreased the parameter Qout which
led to an increase in VT-NLME. This is in line with previ-
ous publications using standard PET PK modeling
approaches, although the extent of the increase is some-
what larger in the present study as data during and im-
mediately after the tariquidar administration were
included (Table 5). This shows that excluding data during
and immediately after P-gp inhibition leads to an under-
estimation of the effect of P-gp inhibition on brain con-
centrations of P-gp substrates. After P-gp inhibition in
humans, VT-2T4K was slightly increased, while a decrease
was observed for VT-NLME. This is likely due to the fact
that, in the standard PET approach, one subject is driving
the average, while with NLME modeling, the model isnaïve, 48-h SE rats, and humans obtained with Logan
, respectively
elinga (2T4K) Nonlinear mixed effects modeling
Cer WB* WB Cer
2.2 (18) 1.5 (18) 1.6 (18) 0.81 (20)
6.1 (9) 7.0 (19) 9.6 (18) 2.4 (21)
2.8-fold 4.6-fold 6.2-fold 4.4-fold
1.5 (6) 1.5 1.6 0.81
3.6 (14) 7.0 9.6 2.4
2.4-fold 4.6-fold 6.2-fold 4.4-fold
- 0.54 (−) 0.51 (−) -
- 0.49 (−) 0.79 (−) -
- No difference 1.5-fold -
ion and Cer at baseline and post-inhibition scan. aLogan and 2T4K results
ans. bIncrease after tariquidar administration for NLME modeling is based on
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simultaneously.
The major findings of this study are as follows: First, it
has been debated whether inhibition of P-gp affects the
transport of substrates across the BBB into the brain
(K1, Qin) or the transport out of the brain (k2, Qout). Two
models have been suggested, i.e., influx hindrance and
efflux enhancement. Influx hindrance can be described
by the ‘gatekeeper’ model, where substrates are trans-
ported back from the lipid layers of the luminal cell
membrane into the blood before they reach the cyto-
plasm. Efflux enhancement can be described by the ‘vac-
uum cleaner’ model [40] which suggests that substrates
can be transported from the endothelial cells or brain
parenchyma back into the blood. Thus, the question
remains if tariquidar enhances brain distribution of (R)-
[11C]verapamil by increasing the influx (K1, Qin) or de-
creasing the efflux (k2, Qout) of the tracer. Our model
clearly indicated that tariquidar enhances brain uptake
of (R)-[11C]verapamil by decreasing Qout of the radiotra-
cer. P-gp inhibition led to an on average sevenfold re-
duction in Qout in rats (3 mg/kg tariquidar), while in
humans (2 mg/kg tariquidar) a twofold reduction in Qout
was observed when all data were included into the
model. When data during and immediately after tariqui-
dar administration were excluded, an average fivefold re-
duction in Qout was observed in rats. Thus, the
reduction in Qout when including the data obtained dur-
ing and after tariquidar administration was more pro-
nounced than when this part was excluded. This
indicates that the effect of tariquidar on P-gp function is
already declining at 2 h after tariquidar administration.
In humans, the tariquidar effect on Qout was apparent
only during and after tariquidar administration and had
completely disappeared in the post-inhibition scan. This
highlights the importance of designing appropriate study
protocols when investigating active transporters at the
BBB as the onset and decline of inhibition is very rapid.
Also, important to point out is that the analysis showed
that Qout and Qin estimates were very similar regardless
of whether the data from the tariquidar administration
period were included or not, i.e., this confirms that the
model is reliable and that only parameters that are
expected to vary over time, e.g. the effect of tariquidar,
are indeed changing.
Second, the study also indicated some regional and
species differences in P-gp inhibition; large tariquidar-
induced decreases in Qout (CS, Th, and Hipp) indicated
strongly enhanced brain uptake of (R)-[11C]verapamil,
while small decreases in Qout (Cer, EC) indicated a weak
enhancement in brain uptake of (R)-[11C]verapamil as
compared with baseline scans (Figure 8). A decrease in
Qout leads to an increased VT-NLME as VT-NLME is
defined as the ratio between Qin and Qout. Thus, thedeveloped NLME model indicated that, after P-gp inhib-
ition, VT-NLME was significantly increased both in naïve
and 48-h post SE rats. Inhibition with 3 mg/kg tariquidar
resulted in regionally different enhancement of brain activ-
ity distribution, with weakest enhancement (low VT-NLME)
in Cer and strongest enhancement (high VT-NLME) in CS
and Th, similar to the findings of Kuntner et al. [10], who
reported lowest VT-2T4K increases in Cer and highest
VT-2T4K increases in Th of naïve rats after adminis-
tration of 3 mg/kg tariquidar. (R)-[11C]verapamil WB
VT-NLME was about threefold lower at baseline in
humans than in rats (0.51 vs. 1.6±0.3) (Table 5). This
is also in good agreement with findings from Bauer
et al. [18] reporting twofold lower VT-2T4K values in
humans than in rats (Table 5). These observed differences
could be due to different expression and transport capacity
of P-gp.
Third, SE (EffSE) was found to increase Vbr1 in most
regions leading to an increase in brain exposure time of
(R)-[11C]verapamil in 48-h post SE rats compared with
controls. This is mainly because an increase in Vbr1 indi-
cates increased distribution of (R)-[11C]verapamil to the
slow equilibrating brain compartment (Vbr2). This in
turn will slow down the elimination of (R)-[11C]verap-
amil from the brain. The difference between the two
groups was largest in FMC (EffSE = 2.3, Table 4). This is
in line with results reported by Syvänen et al. [26], which
showed that Vbr1 in WB was increased 1.3-fold in
kainate-induced post SE rats. In contrast to all other
regions, exposure time was decreased in Cer in 48-h
post SE rats compared with controls (EffSE = 0.924,
Table 4). In line with these findings, Bankstahl et al.
reported an increase of VT-2T4K in FMC, while Cer
showed the largest decrease of VT-2T4K in 48-h post SE
rats compared with controls [9]. The decrease in VT-
2T4K in Cer of 48-h post SE rats was presumably caused
by a twofold upregulation of P-gp as compared with
control rats as revealed by post-mortem immunohisto-
chemical analysis of the brain tissue [9]. Opposite to the
findings presented in this paper, Bankstahl et al. also
reported decreases or non-significant differences be-
tween controls and 48-h post SE rats in CS, Hipp, and
Th. However, when ranking the regional SE-induced dif-
ferences reported in the present study and by Bankstahl
et al., the order is the same: FMC > CS > Hipp > Th >
Cer. Bankstahl et al. found these regional differences
only after partial inhibition of P-gp with 3 mg/kg. In the
present study, all data were analyzed simultaneously in-
cluding data from rats administered with 3 and 15 mg/
kg tariquidar. This may, at least in part, be a reason for
the differences in magnitude of regional differences be-
tween the present study and the study by Bankstahl
et al. The present study showed that the effect of SE was
mainly influencing the distribution of (R)-[11C]verapamil
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across the BBB (Qin, Qout). It was possible to make this
distinction by parameterization of the model using dis-
tribution volumes (the pharmacological term) and clear-
ances instead of rate constants which depend on
distribution volumes and clearances. Again, the effect of
SE was the same when including and excluding data
from the tariquidar administration period which indi-
cated that the model parameter estimates are robust and
do not change when adding or deleting some of the data
set.
Conclusion
This study showed that tariquidar enhances brain uptake
of (R)-[11C]verapamil by decreasing the outflux (Qout) of
the tracer across the BBB. Pilocarpine-induced SE did
not directly influence (R)-[11C]verapamil transport
across the BBB but had an indirect influence on the (R)-
[11C]verapamil exposure time in brain by influencing the
pharmacological volume of distribution in the brain
(Vbr1). For the quantitative analysis of PET data, the
NLME modeling approach used in this study is an inter-
esting supplemental tool to standard PET PK modeling
approaches on individual level to increase mechanistic
knowledge of radiotracer transport across the BBB.
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